Fibrates for primary prevention of cardiovascular disease
Fibrates appear to lower the risk for cardiovascular (CVD) and coronary events in primary prevention without increasing or decreasing overall mortality or non-CVD mortality, but the absolute treatment effects are modest (absolute risk reductions < 1%).
The quality of evidence is downgraded by study llimitations (high loss to foll...
Do you want to read more?
To continue reading this article, you must log in with your personal, organization, or group practice subscription.
For more information or to purchase a personal subscription, click below to see pricing.